RxDoctor Payments Data

David Miedema, MD

General Practice · Somerville, TNNPI 1689962524

Payments from drug & device makers

$505in general payments, 2019–2025

Across 23 payments — averaging $21.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$130
  • AstraZeneca$108
  • Astellas Pharma US Inc$59
  • Dexcom, Inc.$40
  • Novo Nordisk$34
  • GSK$32
  • plus $102 from 5 others

What the payments were for

  • Food & beverage$505100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$505 in reported general payments places this provider in the 65th percentile of 1,632 general practice providers in Tennessee.

See all general practice providers in Tennessee

Medicare billing

Part B allowed, 2024
$91,724
Medicare patients
321
Services billed
1,450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban93$79,779
MounjaroTirzepatide61$76,486
FarxigaDapagliflozin Propanediol72$71,903
OzempicSemaglutide75$69,055
JardianceEmpagliflozin46$56,754
TrulicityDulaglutide50$53,136
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$46,052
RybelsusSemaglutide23$32,246
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$30,117
JanuviaSitagliptin Phosphate22$23,968
LinzessLinaclotide12$15,142
XareltoRivaroxaban17$15,134
Breo ElliptaFluticasone/Vilanterol24$11,875
GlyxambiEmpagliflozin/Linagliptin12$7,137
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$6,020

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$130$129,623111 claims
AstraZenecaFarxiga, Breztri Aerosphere$108$102,020106 claims
Novo NordiskOzempic, Rybelsus$34$101,30198 claims
GSKTrelegy Ellipta, Breo Ellipta$32$57,92667 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,632 general practice providers in Tennessee.

Other general practice in Somerville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →